10-K: Labcorp Reports 7% Revenue Increase in 2024, Driven by Base Business Growth

Labcorp's 2024 annual report reveals a 7% revenue increase, fueled by strong performance in its core diagnostics and biopharma laboratory services.

Summary

• Labcorp's 2024 revenues reached $13,008.9 million, a 7.0% increase from 2023.
• Diluted earnings per share from continuing operations were $8.84.
• The company generated $1,585.8 million in operating cash flow from continuing operations.
• Base Business revenue grew by 4.9% from 2023 to 2024 and 7.4% CAGR versus 2019.
• The Diagnostics Laboratories (Dx) segment contributed 78% of the company's revenues, while Biopharma Laboratory Services (BLS) contributed 22%.
• Dx segment revenues were $10,144.3 million, with an operating income of $1,606.3 million and an operating margin of 15.8%.
• BLS segment revenues were $2,922.6 million, with an operating income of $458.9 million and an operating margin of 15.7%.
• The company invested $839.0 million in strategic business acquisitions during 2024.
• Labcorp repurchased 1.1 million shares of common stock at an average price of $219.57 per share for a total cost of $250.1 million and paid dividends of $243.1 million.
• Capital expenditures were $489.9 million, or 3.8% of revenues.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with revenue growth and strategic acquisitions, but also acknowledges risks and challenges in the regulatory and competitive landscape.

Positives

• Significant reach, breadth, and advancement of the company's offerings have resulted in Base Business revenue growth of 4.9% from 2023 through 2024 and 7.4% versus 2019 compound annual growth rate (CAGR).
• The company signed or completed 10 collaboration transactions with health systems and local and regional laboratories in 2024.
• BLS had provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, including 86% of those specific to oncology, 74% of those submitted by biotechnology companies, and 80% of those submitted by leading and large pharmaceutical companies.
• The company reduced its work-related injury rate per 100 employees by 14.2% and its work-related lost work injury rate per 100 employees by 24.7%.

Negatives

• PAMA resulted in a net reduction in reimbursement revenue of approximately $245.0 million between 2018-2020 from all payers affected by the CLFS.
• Unless implementation of PAMA is further delayed or changed, additional reductions in reimbursements of $100.0 million are expected for 2026 from all payers affected by the CLFS.

Risks

• Changes in government and third-party payer regulations, reimbursement, or coverage policies could adversely affect the company.
• Failure to comply with privacy and security laws and regulations could result in significant fines and penalties.
• Increased competition, including price competition, could have an adverse effect on the company's revenues and profitability.
• The company's operations could be disrupted by events beyond its control, including natural disasters, geopolitical events, and public health crises.
• Cybersecurity incidents and unauthorized access to the company's or its customers' data could harm the company's reputation and adversely affect its business.
• The company may face increased cybersecurity risks due to the number of employees that continue to work remotely.
• The use of AI and machine learning tools in the company's operations and the services of its third-parties may introduce risks that could adversely affect the company's business, financial condition, and reputation.

Future Outlook

The company expects capital expenditures to remain consistent in 2025, primarily in connection with projects to support growth in the company's core businesses, facility expansion and updates, projects related to its LaunchPad initiative, and further acquisition integration initiatives.

Management Comments

• Through leadership in science, technology and innovation, the Company provides vital information and services to help its customers make clear and confident health decisions and helps millions of people improve health and improve lives.
• The Company is expanding its role in the rapidly evolving healthcare market by strengthening its positions across its portfolio of capabilities, growing strategic opportunities that drive new business, and differentiating its unique offerings, capabilities, and financial performance.

Industry Context

The report highlights industry consolidation trends, the increasing importance of relationships with hospital-based health systems, and the competitive landscape in both the commercial laboratory and drug development services businesses.

Comparison to Industry Standards

• The U.S. clinical laboratory testing industry generated revenues of more than $80 billion in 2024.
• The global pharmaceutical industry spent more than $200 billion on R&D in 2024.
• CMS has estimated that, as of March 2024, there were nearly 320,000 clinical laboratories of all types, including approximately 9,200 hospital-based laboratories, just under 123,000 physician-office laboratories, and approximately 8,500 independent clinical and anatomic pathology laboratories in the U.S.

Legal Proceedings

• The Company is involved in pending and threatened litigation related to the AMCA Incident, as well as various government and regulatory inquiries and processes.
• Ravgen Inc. filed a patent infringement lawsuit against the Company alleging infringement of two Ravgen-owned U.S. patents.
• The Company was served with a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Central District of California, alleging that visually impaired patients are unable to use the Company's touchscreen kiosks at Company patient service centers in violation of the Americans with Disabilities Act and similar California statutes.
• The Company was served with a putative class action lawsuit, Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds, et al. v. Laboratory Corporation of America, Laboratory Corporation of America Holdings, and Meta Platforms, Inc., filed in the U.S. District Court for the Northern District of California, alleging that the Company's website includes a tracking code created by Meta, known as the Meta Pixel, that sent information related to Plaintiffs and their online activities to Meta.

Stakeholder Impact

• The company's performance impacts shareholders through stock value and dividends.
• Employees are affected by talent initiatives, compensation, and well-being programs.
• Customers benefit from the company's innovative offerings and services.
• The company's community engagement efforts impact underserved communities through strategic philanthropy and volunteerism.

Next Steps

• The Company continues to evaluate acquisition opportunities that leverage the Company's core competencies, complement existing scientific and technological capabilities, increase the Company's presence in key geographic, therapeutic and strategic areas, and meet or exceed the Company's financial criteria.
• The Company will continue to evaluate opportunities for strategic deployment of capital in light of market conditions.

Key Dates